Guggenheim Reiterates Buy on Vera Therapeutics, Maintains $56 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $56 price target.
April 05, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan reiterates a Buy rating on Vera Therapeutics with a $56 price target.
The reiteration of a Buy rating and maintenance of a $56 price target by a reputable analyst like Vamil Divan from Guggenheim is likely to instill confidence among investors and could positively influence Vera Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100